Skip to main content
. 2006 Jun 14;26(24):6450–6457. doi: 10.1523/JNEUROSCI.0491-06.2006

Figure 4.

Figure 4.

Effects of SKF 82958 on somatic withdrawal signs. Rats were implanted with placebo or morphine pellets and 3 d later were treated subcutaneously with a mixture of naloxone (nal; 0.1 mg/kg) and SKF 82958 (SKF; 1.0 mg/kg), and somatic withdrawal behaviors were scored for 15 min. SKF 82958 reduced the total incidence of somatic withdrawal behaviors (A) as well as wet dog shakes (B) and teeth chattering (C) but not cage crossings (D) (means ± SEM). **p < 0.05 compared with effects of naloxone alone in morphine-dependent rats; ††p < 0.01 comparing bracketed groups, Fisher’s protected t tests, eight rats per group.